Roche says combination therapy met primary endpoint

A combination therapy of pertuzumab, trastuzumab and docetaxel for women with HER2-positive metastatic breast cancer has met its primary endpoint of progression-free survival in a Phase 3 study, according to the trial’s sponsor, Roche.